logo-loader
viewCymaBay Therapeutics

CymaBay Therapeutics' shares shoot up on phase 2 data for liver drug

The results were from the ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC)

livercancer_596ccc2790147.jpg
Primary biliary cholangitis (PBC) is a life-threatening and life-limiting chronic cholestatic liver disease

Shares in CymaBay Therapeutics Inc (NASDAQ:CBAY) rose over 25% to $7.08 on Monday on positive phase 2 trial results.

The results were from the ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a life-threatening and life-limiting chronic cholestatic liver disease.

Seladelpar is in development for the treatment of liver diseases PBC and Nonalcoholic steatohepatitis (NASH).

After sharing preliminary results from this study, the FDA has agreed to allow continuation of seladelpar treatment beyond six months for the 5 mg and 10 mg doses, the group revealed.

"The data emerging from this study are impressive and support our hypothesis that lower doses of seladelpar than previously studied retain strong efficacy without raising a concern with transaminase elevations," said Professor Gideon Hirschfield, Centre for Liver Research at the University of Birmingham, UK

"We also see that seladelpar activity is not associated with drug-induced itch, an important benefit for patients with PBC. If these results are maintained over longer periods, we think that seladelpar could offer patients significant advantages over existing treatments," he added.

Quick facts: CymaBay Therapeutics

Price: 1.7 USD

NASDAQ:CBAY
Market: NASDAQ
Market Cap: $116.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medicenna Therapeutics completes Phase 2B study on cancer drug mdna55

Medicenna Therapeutics (TSE: MDNA) CFO Elizabeth Williams joined Steve Darling from Proactive Vancouver at LD MIcrocap Conference in Vancouver with news about their lead drug mdma55. Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and commercialization...

9 hours, 20 minutes ago

2 min read